The study developed and validated a rapid LC-MS/MS method for quantifying cefazolin in capillary whole blood collected via VAMS, plasma, and plasma ultrafiltrate, showing robust performance across matrices and successful application in a pediatric pilot cohort for therapeutic drug monitoring.
A UPLC-MS/MS method for linezolid and metabolites in oral fluid and VAMS capillary blood satisfied ICH M10 validation requirements. Linezolid concentrations correlated strongly with venous plasma in both matrices, offering a non‑invasive option for therapeutic drug monitoring, whereas metabolites were systematically underestimated in VAMS and seldom detectable in oral fluid, restricting metabolite measurement.
A systematic review found mixed economic evidence for microsampling in therapeutic drug monitoring; one study reported no cost reduction with DBS home-sampling, €688 versus €676, whilst another predicted savings up to 61%. The authors caution that more work is required to assess costs alongside clinical outcomes and optimise logistics for decentralised implementation.
This study validated a method for quantifying fluconazole using the Mitra device, demonstrating sufficient accuracy and precision for therapeutic drug monitoring in paediatric patients.
The study compared quantitative dried blood spot (qDBS) and volumetric absorptive microsampling (VAMS) devices for measuring ganciclovir levels in capillary blood from pediatric renal transplant recipients. This comparison provides evidence for choosing between microsampling devices in therapeutic drug monitoring, supporting decentralised sampling approaches that reduce patient burden while maintaining analytical accuracy.